|
INFORM: Information Needed for Optimal Regulation of Mycophenolate- A REMS Activity
Target Audience
The target audience for this initiative includes obstetricians, gynecologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and care team members involved in the treatment of women across their reproductive lifespan who may have been prescribed mycophenolate products.
Program Overview
Clinicians who work with women of childbearing age who are, or will be, taking mycophenolate must ensure that their patients receive appropriate counseling... |
|
Hot Topics in Lupus: SLE Pathophysiology
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
Hot Topics in Lupus: Individualizing Steroid-Sparing Regimens
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
Hot Topics in Lupus: Targeted Biologic Treatment Options
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |